Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14735488 | 0.97 | GPR119 (0.47) | GPR119FAAHPDE4APDE4BPDE4C | |
| SCHEMBL14735501 | 0.94 | GPR119 (0.44) | GPR119FAAHPDE4APDE4BPDE4C | |
| SCHEMBL14735393 | 0.89 | GPR119 (0.43) | GPR119PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14735410 | 0.86 | KMT5A (0.42) | PDE4B | |
| SCHEMBL14735456 | 0.85 | TLR8 (0.42) | PDE4B | |
| SCHEMBL14735601 | 0.81 | GPR119 (0.42) | GPR119FAAHPDE4APDE4BPDE4C | |
| SCHEMBL14734906 | 0.81 | CHRM2 (0.41) | GPR119PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14734956 | 0.80 | GPR119 (0.43) | GPR119PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14734955 | 0.80 | GPR119 (0.43) | GPR119PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14735000 | 0.80 | GPR119 (0.41) | GPR119PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2565192-B9 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| EP-2565192-B1 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-08-12 | — | — | EP | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2565192-A1 | ANTICANCER AGENT | The University of Tokyo (JP) | 2013-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102776-A1 | ANTICANCER AGENT | PIM1, PIM3, PIM2 | GPR119 1923/4885FAAH 4769/4885PDE4A 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.